Recent preclinical studies have suggested that the androgen-mediated AR signaling promotes bladder cancer progression, and blocking this signaling with enzalutamide can strongly impair bladder cancer cell growth [16,17,18]. Here, AR is linked to urinary bladder carcinoma.